BioInsights - Overcoming the immune-related shortfalls of AAV

Overcoming the immune-related shortfalls of AAV

Cell & Gene Therapy Insights 2022; 8(4), 517–521

DOI: 10.18609/cgti.2022.076

Published: 9 May 2022
Genine Winslow

Genine Winslow is the CEO and co-founder of Chameleon Biosciences, a biotechnology company she founded in 2017 focused on safer, more effective gene therapies. At Chameleon, Genine combines her backgrounds in both immunology and gene therapy to engineer a next generation AAV based vector for systemic repeat dosing for children and adults who today cannot be treated with conventional gene therapies. Prior to Chameleon, Winslow has led gene therapy scientific initiatives at multiple companies including Audentes Therapeutics, BioMarin, BlueBird Bio, and Cell Genesys.

On March 30th 2022, David McCall, Editor, Cell and Gene Therapy Insights spoke to Genine Winslow about overcoming the immune-related shortfalls of AAV. This article has been written based on that interview.